Nuclear and cytoplasmic expression of ErbB-4 in prostate cancer

R. Ben-Yosef, D. Sarid, A. Vexler, G. Lidawi, M. Inbar, S. Marmor, A. Starr, N. Yaal Hahoshen

Research output: Contribution to journalArticlepeer-review

Abstract

Purpose: To evaluate cytoplasmic and nuclear ErbB-4 expression in prostate cancer specimens and its association with outcome. Basic procedures: Specimens of 50 prostate cancer patients were investigated for ErbB-4 overexpression using immunohisto-chemistry staining. Cytoplasmic and nuclear staining was graded as 0-3 according to its intensity. The prognostic parameters were tumor stage, PSA level, Gleason score, probability of positive lymph nodes (Partin's tables and Roach equation), and 5-year disease free survival (Kattan nomogram). Main findings: Overexpression of ErbB-4 (≥1) was detected in 30 (60%) patients and overexpression using cytoplasmic and nuclear staining was ≥2 in 19 (38%) and 17 (34%) patients, respectively. In only one third of the specimens was there any similarity between the 2 types of staining. Advanced tumor stage, high pretreatment PSA levels and high Gleason scores were evenly distributed among the patients with low (≤1) and intermediate/high (≥2) ErbB-4 expression. The probability of lymph node involvement and 5-year disease free survival were similar in both types of staining. Principal conclusions: ErbB-4 was overexpressed (cytoplasmic and nuclear staining) in approximately one third of prostate cancer patients. The rate of similarity between the 2 staining types was only 33%: overexpression was evenly distributed among intermediate/high and low risk prostate cancer patients with both staining methods.

Original languageEnglish
Pages (from-to)181-185
Number of pages5
JournalInternational Journal of Biological Markers
Volume22
Issue number3
DOIs
StatePublished - 2007
Externally publishedYes

Keywords

  • Cytoplasmic staining
  • ErbB-4
  • Nuclear staining
  • Prostate cancer

Fingerprint

Dive into the research topics of 'Nuclear and cytoplasmic expression of ErbB-4 in prostate cancer'. Together they form a unique fingerprint.

Cite this